BridgeBio have demonstrably improved its progress of an new therapy for amyloid heart disease, leveraging the compound. Initial patient data suggests promising outcomes for individuals affected with a severe disease. https://biotech595790.estate-blog.com/40908153/company-improves-cardiac-amyloidosis-therapy-using-attruby